Silence Therapeutics plc, (“Silence” or “the Company”), One of the experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, recently announced the appointment of J.P. Gabriel as Chief Technical Operations Officer (CTOO) following the retirement of Jørgen Wittendorff, SVP, Technical Operations. In this role, J.P. is responsible for Manufacturing, Process and Analytical Development and Supply Chain.
“We are pleased to welcome J.P. to Silence during this very exciting time,” said Craig Tooman, President and CEO of Silence. “He brings over 25 years of industry experience in supply chain, quality assurance and manufacturing that will be critical as we continue to advance our clinical stage pipeline. We also want to thank Jørgen for his many contributions to Silence over the years.”
J.P. Gabriel commented, “Silence has a very promising clinical pipeline and siRNA technology platform with potential to address both rare and common genetic diseases. I am grateful for the opportunity to work with the team to help deliver the pipeline while continuing to build an effective and agile organization that is set for growth.”
Mr. Gabriel has over 25 years of international pharmaceutical industry experience across multiple therapeutic modalities. He has held leadership roles in Manufacturing, Quality, Validation and Supply Chain with firms such as Sanofi-Pasteur, Wyeth (now Pfizer) and Genentech/Roche. He most recently served as SVP, Technical Operations at Ocugen, which includes AAV gene therapy, vaccine, and cell therapy development. Before Ocugen, he spent over five years at Ultragenyx where he was responsible for Biologics and mRNA manufacturing for programs spanning clinical and commercial stages of the development lifecycle. Mr. Gabriel holds an Honors B.Sc. from the University of Guelph in Ontario, Canada and an Advanced Certificate in Regulatory Affairs from the University of San Diego in California.
Also on biotechnology companies:
Vesigen Therapeutics onboards Rakhshita Dhar to Board of Directors
Akston Biosciences appoints John T. Preston as Board of Directors
